{"id":60144,"date":"2024-10-09T04:04:18","date_gmt":"2024-10-09T02:04:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-grant-of-stock-options\/"},"modified":"2024-10-09T04:04:18","modified_gmt":"2024-10-09T02:04:18","slug":"devonian-announces-the-grant-of-stock-options","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-grant-of-stock-options\/","title":{"rendered":"Devonian Announces the Grant of Stock Options"},"content":{"rendered":"
\n

QUEBEC CITY–(BUSINESS WIRE)–Devonian Health Group Inc. (\u201cDevonian<\/b>\u201d or the \u201cCorporation<\/b>\u201d) (TSXv: GSD<\/b>), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces that its Board of Directors has approved the grant of options to purchase Shares (the \u201cOptions<\/b>\u201d) at an exercise price of $0.16 for a period of 10 years from the date of grant. An aggregate of 3,298,611 Options was granted to officers of the Corporation. These Options are exercisable on the grant date.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nAbout Devonian<\/b>\n<\/p>\n

\nDevonian is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian\u2019s core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian\u2019s focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines.\n<\/p>\n

\nDevonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Inc., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies.\n<\/p>\n

\nDevonian was incorporated in 2015 and is headquartered in Qu\u00e9bec, Canada where it owns a state-of-the art extraction facility with full traceability \u2018from the seed to the pill\u2019. Devonian is traded publicly on the TSX Venture Exchange (the \u201cExchange<\/b>\u201d) (TSXV: GSD<\/b>) and on OTCQB exchange (OTCQB: DVHGF<\/b>).\n<\/p>\n

\nFor more information, visit www.groupedevonian.com<\/a>\n<\/p>\n

\nForward Looking Statements<\/b>\n<\/p>\n

\nThis press release contains forward-looking statements about Devonian\u2019s objectives, strategies and businesses that involve risks and uncertainties. These statements are \u201cforward-looking\u201d because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Devonian\u2019s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian\u2019s prospectus dated April 21st<\/sup>, 2017 under the heading \u201cRisk Factors\u201d related to Devonian\u2019s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.\n<\/p>\n

\nNeither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMr. Luc Gr\u00e9goire
\n
President and Chief Executive Officer
\n
Devonian Health Group Inc.
\n
Telephone: 1 (450) 979-2916
\n
Courriel: investors@groupedevonian.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

QUEBEC CITY–(BUSINESS WIRE)–Devonian Health Group Inc. (\u201cDevonian\u201d or the \u201cCorporation\u201d) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces that its Board of Directors has approved the grant of options to purchase Shares (the \u201cOptions\u201d) at an exercise price of $0.16 for a … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60144","6":"format-standard","7":"category-industry"},"yoast_head":"\nDevonian Announces the Grant of Stock Options - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/devonian-announces-the-grant-of-stock-options\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Devonian Announces the Grant of Stock Options - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"QUEBEC CITY–(BUSINESS WIRE)–Devonian Health Group Inc. (\u201cDevonian\u201d or the \u201cCorporation\u201d) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces that its Board of Directors has approved the grant of options to purchase Shares (the \u201cOptions\u201d) at an exercise price of $0.16 for a ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/devonian-announces-the-grant-of-stock-options\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-09T02:04:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20241008196755\/en\/681971\/22\/logodevonian2.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-grant-of-stock-options\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-grant-of-stock-options\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Devonian Announces the Grant of Stock Options\",\"datePublished\":\"2024-10-09T02:04:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-grant-of-stock-options\\\/\"},\"wordCount\":572,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-grant-of-stock-options\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241008196755\\\/en\\\/681971\\\/22\\\/logodevonian2.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-grant-of-stock-options\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-grant-of-stock-options\\\/\",\"name\":\"Devonian Announces the Grant of Stock Options - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-grant-of-stock-options\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-grant-of-stock-options\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241008196755\\\/en\\\/681971\\\/22\\\/logodevonian2.jpg\",\"datePublished\":\"2024-10-09T02:04:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-grant-of-stock-options\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-grant-of-stock-options\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-grant-of-stock-options\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241008196755\\\/en\\\/681971\\\/22\\\/logodevonian2.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241008196755\\\/en\\\/681971\\\/22\\\/logodevonian2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-announces-the-grant-of-stock-options\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Devonian Announces the Grant of Stock Options\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Devonian Announces the Grant of Stock Options - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-grant-of-stock-options\/","og_locale":"en_US","og_type":"article","og_title":"Devonian Announces the Grant of Stock Options - Pharma Trend","og_description":"QUEBEC CITY–(BUSINESS WIRE)–Devonian Health Group Inc. (\u201cDevonian\u201d or the \u201cCorporation\u201d) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces that its Board of Directors has approved the grant of options to purchase Shares (the \u201cOptions\u201d) at an exercise price of $0.16 for a ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-grant-of-stock-options\/","og_site_name":"Pharma Trend","article_published_time":"2024-10-09T02:04:18+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20241008196755\/en\/681971\/22\/logodevonian2.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-grant-of-stock-options\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-grant-of-stock-options\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Devonian Announces the Grant of Stock Options","datePublished":"2024-10-09T02:04:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-grant-of-stock-options\/"},"wordCount":572,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-grant-of-stock-options\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241008196755\/en\/681971\/22\/logodevonian2.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-grant-of-stock-options\/","url":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-grant-of-stock-options\/","name":"Devonian Announces the Grant of Stock Options - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-grant-of-stock-options\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-grant-of-stock-options\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241008196755\/en\/681971\/22\/logodevonian2.jpg","datePublished":"2024-10-09T02:04:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-grant-of-stock-options\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/devonian-announces-the-grant-of-stock-options\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-grant-of-stock-options\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20241008196755\/en\/681971\/22\/logodevonian2.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20241008196755\/en\/681971\/22\/logodevonian2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/devonian-announces-the-grant-of-stock-options\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Devonian Announces the Grant of Stock Options"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60144","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60144"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60144\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60144"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60144"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60144"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}